Research programme: pathogen extracting therapies - Opsonix

Drug Profile

Research programme: pathogen extracting therapies - Opsonix

Alternative Names: FcMBL - Opsonix

Latest Information Update: 28 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard University
  • Developer Harvard University; Opsonix
  • Class Immunoglobulin Fc fragments; Recombinant proteins
  • Mechanism of Action Immunostimulants; Mannose binding lectin modulators; Pattern recognition receptor agonists; Phagocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Infections; Sepsis

Most Recent Events

  • 08 Oct 2015 Preclinical trials in Infections in USA (unspecified route)
  • 08 Oct 2015 Preclinical trials in Sepsis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top